Biosimilars Growth in EU: Market Forecast Post-Biologics Patent Expiry

Key Takeaways

• Market growth trajectory: The European biosimilars market is projected to expand from USD 4.36 billion in 2024 to USD 23.39 billion by 2032 at a compound annual growth rate (CAGR) of 23.5%, with an alternative forecast suggesting growth from USD 16.4 billion in 2026 to USD 44.3 billion by 2033 at a CAGR of 15.3%.
• Patent expiry catalyst: Expiration of key biologic patents is driving biosimilar market entry across Oncology, Immunology, and Endocrinology therapeutic areas, enabling increased competition and cost savings.
• Reimbursement support: Favorable reimbursement policies in countries such as Germany, combined with demographic shifts toward an aging population and rising chronic disease prevalence, are accelerating biosimilar adoption across European healthcare systems.
• Pricing pressure dynamics: Intensifying competition between biosimilar manufacturers and originator biologics is expected to drive significant pricing pressures, reshaping market profitability and access strategies across the European Union.

The European biosimilars market is poised for substantial expansion in the post-patent expiry era, with market valuations projected to grow at accelerated rates through 2033. The European Medicines Agency (EMA) regulatory environment, combined with supportive reimbursement frameworks and demographic tailwinds, is creating favorable conditions for biosimilar penetration across major European markets. Why it matters: This growth trajectory offers significant cost savings and expanded access to biologic therapies for European patients while intensifying competitive pressures on both biosimilar manufacturers and originator biologic companies.

Market Overview: Biosimilars in the European Healthcare Landscape

Biosimilars are biologic medicinal products highly similar to an already approved reference biologic medicine, with no clinically meaningful differences in terms of efficacy, safety, or purity. Unlike generic drugs—which are chemically identical to their reference products—biosimilars are manufactured in living systems and exhibit inherent variability. The EMA established a comprehensive regulatory pathway for biosimilar approval, requiring comparative clinical immunogenicity and pharmacokinetic studies to demonstrate biosimilarity to the reference product.

The European biosimilars market encompasses therapeutic agents across multiple disease areas, including monoclonal antibodies, fusion proteins, and recombinant cytokines used in oncology, immunology, and endocrinology. As blockbuster biologic patents expire—particularly for agents such as infliximab, adalimumab, and trastuzumab—the market opportunity for biosimilar developers has expanded dramatically. The EMA's established biosimilar regulatory framework has facilitated faster market entry compared with some other regulatory jurisdictions, positioning Europe as a leading market for biosimilar competition.

Market Dynamics: Growth Drivers and Valuation Forecasts

The European biosimilars market is forecasted to experience rapid expansion driven by multiple interconnected factors. According to market projections, the biosimilars market valuation is expected to grow from USD 4.36 billion in 2024 to USD 23.39 billion by 2032, representing a CAGR of 23.5%. An alternative forecast model estimates market growth from USD 16.4 billion in 2026 to USD 44.3 billion by 2033, with a CAGR of 15.3%. These divergent projections reflect uncertainty regarding adoption rates and competitive intensity, yet both scenarios indicate substantial market expansion.

Primary growth drivers include patent expiration of key reference biologics, which removes regulatory exclusivity barriers and enables biosimilar market entry. Cost savings associated with biosimilar utilization—typically 20–40% price reductions compared with reference products—are driving healthcare system adoption, particularly in budget-conscious European markets. Demographic trends, including an aging European population with increased prevalence of chronic inflammatory, oncologic, and endocrine diseases, are expanding the patient population eligible for biologic therapies. Supportive reimbursement policies, particularly in major markets such as Germany, are facilitating biosimilar uptake by ensuring healthcare provider and patient access.

Compared with markets with restrictive biosimilar reimbursement frameworks, European healthcare systems with transparent health technology assessment (HTA) processes and established biosimilar reimbursement pathways are experiencing accelerated adoption. Germany's favorable reimbursement environment, which includes established biosimilar switching protocols and price-based competition mechanisms, serves as a model for biosimilar market penetration across the European Union.

Regulatory Context: The EMA's Role in Biosimilar Market Access

The EMA has established a well-defined regulatory pathway for biosimilar approval, requiring comparative analytical, animal toxicity, and clinical pharmacology studies, followed by comparative clinical immunogenicity and efficacy data. This framework, while more stringent than generic drug approval requirements, is less burdensome than approval of a novel biologic. The EMA's biosimilar guidance documents have evolved to reflect scientific advances, enabling more efficient development pathways and faster market access timelines.

The EMA's centralized procedure for biosimilar approval has created a unified European market, allowing approved biosimilars to be marketed across all European Union member states following a single regulatory decision. This contrasts with fragmented national approval processes in some non-European markets, providing biosimilar manufacturers with significant commercial advantages in Europe. The EMA's transparent assessment process and published scientific opinions have also enhanced healthcare provider confidence in biosimilar safety and efficacy profiles.

Competitive Landscape and Pricing Pressures

The biosimilar market is characterized by increasing competitive intensity as multiple manufacturers develop biosimilars to the same reference products. Patent expiry of blockbuster biologics has triggered biosimilar development pipelines targeting agents with substantial treatment populations, including TNF-alpha inhibitors, anti-VEGF monoclonal antibodies, and insulin glargine biosimilars. This competitive convergence is expected to drive significant pricing pressures, with multiple biosimilar entrants competing on price and potentially forcing originator biologic manufacturers to implement lifecycle management strategies, including patient support programs and indication expansions.

Originator biologic manufacturers are responding to biosimilar competition through various strategies, including aggressive pricing actions, enhanced patient support programs, and development of next-generation biologics with improved efficacy or safety profiles. Healthcare systems across the European Union are leveraging biosimilar competition to negotiate lower prices for both biosimilars and reference products, creating a virtuous cycle of cost containment and improved patient access.

What to watch next: The European biosimilars market will likely experience continued consolidation among biosimilar manufacturers, with larger pharmaceutical companies acquiring smaller biosimilar developers to build comprehensive biosimilar portfolios and achieve economies of scale in manufacturing and distribution.

Market Impact: Patient Access and Healthcare System Benefits

The expansion of the European biosimilars market is expected to substantially improve patient access to biologic therapies by reducing treatment costs and enabling healthcare systems to treat larger patient populations within fixed budgets. In oncology, biosimilar availability for agents such as trastuzumab and bevacizumab is anticipated to reduce treatment costs and improve access to targeted cancer therapies across European healthcare systems. In immunology, biosimilar TNF-alpha inhibitors and anti-IL-6 agents are expanding treatment options for patients with rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory conditions. In endocrinology, biosimilar insulin glargine and other insulin analogs are improving access to insulin therapy for patients with diabetes across Europe.

Healthcare policymakers across the European Union are recognizing biosimilars as a key mechanism for controlling healthcare expenditures while maintaining therapeutic efficacy. Reimbursement policies that encourage biosimilar utilization through pricing incentives, automatic substitution protocols, and prescriber education programs are expected to accelerate biosimilar market penetration. Countries with established biosimilar reimbursement frameworks and healthcare provider engagement strategies are experiencing higher biosimilar adoption rates, demonstrating the importance of policy alignment with market dynamics.

Future Outlook: Strategic Positioning in a Competitive Market

The European biosimilars market is expected to maintain robust growth through 2033 as additional biologic patents expire and healthcare systems increasingly prioritize cost containment. Pharmaceutical companies seeking to maximize market share in the biosimilars space must strategically position themselves to capitalize on patent expiries, develop differentiated biosimilar portfolios, and establish strong relationships with healthcare providers and payers across major European markets.

Biosimilar manufacturers will likely pursue strategies focused on therapeutic area specialization, geographic market prioritization, and development of combination therapies or next-generation biosimilars with enhanced properties. Originator biologic companies will continue to pursue lifecycle management tactics, including indication expansions, combination therapy development, and patient support programs to maintain market share in the face of biosimilar competition.

The competitive dynamics within the European biosimilars market are expected to create opportunities for companies with strong regulatory expertise, manufacturing capabilities, and market access relationships. Sustained pricing pressures will require pharmaceutical companies to optimize manufacturing efficiency, develop cost-effective distribution strategies, and demonstrate clear value propositions to healthcare payers and providers.

Frequently Asked Questions

References

1. European biosimilars market valuation and growth forecasts (2024–2033): Projected growth from USD 4.36 billion in 2024 to USD 23.39 billion by 2032 (CAGR 23.5%) and alternative forecast from USD 16.4 billion in 2026 to USD 44.3 billion by 2033 (CAGR 15.3%), driven by patent expiry of key biologics, cost savings, aging population, chronic disease prevalence, and favorable reimbursement policies.

References

1. European Medicines Agency. EMA approval. Accessed 2026-04-26.